Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its ...
combination therapy for treating adults with KRAS G12C-mutated metastatic colorectal cancer. "Amgen opens new drug substance facility in North Carolina, US" was originally created and published by ...
Amgen Inc.'s Q4 2024 earnings beat expectations ... Lumakras is being advanced to Phase 3 studies in KRAS-g12c mutated NSCLC and colorectal cancer. Lumakras Q4 sales were $85M in 2024, however ...
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial on a clinical hold, the company announced Feb. 4. Amgen has not detailed ...
Amgen said Tuesday that the Food and Drug Administration has ordered a hold on a study of the company’s early-stage obesity candidate, another potential setback in the company’s efforts to ...
Three years after beginning construction in southwestern Wake County, the pharmaceutical company Amgen celebrated the completion of its $550 million manufacturing plant in the town of Holly ...
pembrolizumab plus chemotherapy, is enrolling patients with first-line KRAS G12C–mutated and PD ... prepared in accordance with GAAP. Amgen discovers, develops, manufactures and delivers ...
Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack. The Thousand Oaks, California-based drugmaker didn ...
Shares of Amgen started crashing in early November and didn’t improve when the company released data from a Phase 2 clinical trial for its weight-loss candidate MariTide. That plunge has set the ...
With a ribbon cutting at one facility and a groundbreaking for another Friday, Amgen takes another concrete step towards a promise to create hundreds of jobs in Holly Springs. The $1.02 billion ...